NASDAQ:SCPH - Scpharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.09 -0.40 (-7.29 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$5.49
Today's Range$5.02 - $5.50
52-Week Range$5.02 - $18.17
Volume63,900 shs
Average Volume108,211 shs
Market Capitalization$101.80 million
P/E Ratio-0.63
Dividend YieldN/A
BetaN/A
Scpharmaceuticals logoscPharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting. Its product pipeline also includes scFurosemide, a loop diuretic for the management of edema in patients with decompensated heart failure; scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.

Receive SCPH News and Ratings via Email

Sign-up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SCPH
CUSIPN/A
Phone617-517-0730

Debt

Debt-to-Equity Ratio0.10
Current Ratio19.23
Quick Ratio19.23

Price-To-Earnings

Trailing P/E Ratio-0.63
Forward P/E Ratio-2.29
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$6.02 per share
Price / Book0.85

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees29
Outstanding Shares18,540,000
Market Cap$101.80

The Truth About Cryptocurrencies

Scpharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions

What is Scpharmaceuticals' stock symbol?

Scpharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."

How were Scpharmaceuticals' earnings last quarter?

Scpharmaceuticals Inc (NASDAQ:SCPH) released its quarterly earnings results on Monday, May, 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.04. View Scpharmaceuticals' Earnings History.

What price target have analysts set for SCPH?

3 Wall Street analysts have issued 1 year price objectives for Scpharmaceuticals' stock. Their forecasts range from $12.00 to $14.00. On average, they anticipate Scpharmaceuticals' share price to reach $12.6667 in the next year. This suggests a possible upside of 148.9% from the stock's current price. View Analyst Ratings for Scpharmaceuticals.

What is the consensus analysts' recommendation for Scpharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scpharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Scpharmaceuticals' key competitors?

Who are Scpharmaceuticals' key executives?

Scpharmaceuticals' management team includes the folowing people:
  • Mr. John H. Tucker, Pres, CEO & Director (Age 55)
  • Dr. Troy A. Ignelzi, Chief Financial Officer (Age 50)
  • Mr. Abraham Ceesay, Chief Operating Officer (Age 40)
  • Dr. Pieter Muntendam M.D., Consultant (Age 60)
  • Katherine Taudvin, Director of Corp. Devel. & Investor Relations

When did Scpharmaceuticals IPO?

(SCPH) raised $96 million in an IPO on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Has Scpharmaceuticals been receiving favorable news coverage?

Media coverage about SCPH stock has trended somewhat negative recently, according to Accern. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Scpharmaceuticals earned a media sentiment score of -0.06 on Accern's scale. They also gave media coverage about the company an impact score of 47.53 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Scpharmaceuticals?

Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Scpharmaceuticals' stock price today?

One share of SCPH stock can currently be purchased for approximately $5.09.

How big of a company is Scpharmaceuticals?

Scpharmaceuticals has a market capitalization of $101.80 million. The company earns $-23,810,000.00 in net income (profit) each year or ($8.04) on an earnings per share basis. Scpharmaceuticals employs 29 workers across the globe.

How can I contact Scpharmaceuticals?

Scpharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected]


MarketBeat Community Rating for Scpharmaceuticals (NASDAQ SCPH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  48 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  91
MarketBeat's community ratings are surveys of what our community members think about Scpharmaceuticals and other stocks. Vote "Outperform" if you believe SCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.